RELX-TECHNOLOGY
RELX Technology today announced the company has started operations at its newly-established e-cigarette bioscience laboratory to conduct systematic research on the effects of e-cigarettes through in vivo and in vitro tests, as well as conduct pre-clinical safety assessments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005346/en/
The bioscience laboratory, located in International Bioindustry Valley, Shenzhen is currently conducting research on the impact of RELX products on animal cardiovascular, respiratory, and nervous systems, in order to better carry out a comprehensive impact evaluation of vapor products.
“Science is the foundation of trust. As the industry leader, we have the responsibility to expand the borders of e-cigarette science and explore the unknown,” said Kate Wang, founder and CEO of RELX.
At the RELX Lab Open Day, RELX also announced its plan to establish a “1+4” scientific research approach—i.e. anchored by Platform Development, followed by Toxicological Assessment, Clinical Assessment, Perception Behavior Study and Long Term Assessment.
According to Public Health England, e-cigarettes are 95% less harmful to health than smoking and have the potential to help smokers quit smoking. Many consumers have recognized e-cigarettes as a better alternative to traditional combustible cigarettes.
There are still many areas that require further long-term research, such as the actual harm reduction elements of e-cigarettes, the maximization of their harm reduction, and other potential effects of vaping.
“E-cigarettes are sometimes viewed with suspicion because we have incomplete knowledge,” said Yilong Wen, RELX Co-founder and Head of Science, Research and Development and Supply Chain, “The RELX bioscience lab’s mission is to explore the unknown. We want to collect evidence through a scientific approach and strive to prove the potential for e-cigarettes to be less harmful, and in doing so, provide users the option to choose an alternative.
To ensure the reliability and quality of RELX products, RELX established a chemical and physical laboratory in 2018. The laboratory is certified by the internationally recognized China National Accreditation Service for Conformity Assessment. RELX started its groundbreaking research on the toxicological and pharmacological study on its products in 2019, and the new bioscience lab will focus on vivo and in vitro tests, as well as conduct pre-clinical safety assessments in 2020.
“The toxicological and pharmacological studies focus on the effects of RELX’s products,” said Xingtao Jiang, Head of RELX Lab, “For example, does it affect DNA or chromosomes, and what are the ingredients’ long-term impact on body organs and tissues? There is still a lot of research to be done.”
Xingtao Jiang also announced five preliminary findings from RELX’s research so far. Among these were that according to the data, the levels of harmful substances such as benzene and four TSNAs (Tobacco-specific N-nitrosoamines) emitted by RELX products are lower than those found in combustible cigarette smoke by over 99.1 percent and 99.8 percent respectively.
RELX is currently conducting research projects on different topics with six universities including the Sun Yat-sen University and Shenzhen Institutes of Advanced Technology, the Chinese Academy of Sciences, two hospitals and nine scientific research institutions.
ABOUT RELX Technology
Founded in January 2018, RELX is Asia’s leading e-cigarette brand. RELX independently develops its e-cigarette products at its R&D center in Shenzhen, China. RELX’s mission is to empower adult smokers through technology, product and science, ethically. RELX continues to make significant investments in R&D, e-liquid testing and new product development. The company has attracted global talents from Uber, Proctor and Gamble, Huawei, Beats, and L’Oréal. RELX investors include top venture capital firms Source Code Capital, IDG Capital, and Sequoia Capital.
Website: https://relxnow.com
Twitter: @Relxtech
Facebook: @Relxnow
Instagram: relxtech
Linkedin: RELX Technology
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer20.1.2026 13:00:00 CET | Press release
Update based on real-world evidence from the FLEX Study presented at the 2025 San Antonio Breast Cancer Symposium Agendia, Inc., a leader in precision oncology for breast cancer, today announced that the updated NCCN Clinical Practice Guidelines in Oncology1 (NCCN Guidelines®) now recognize that MammaPrint® + BluePrint® can help identify a subset of hormone receptor positive, HER2-negative (HR+/HER2–) early-stage breast cancer (EBC) patients most likely to benefit from anthracycline-based chemotherapy. “I am delighted that oncologists finally have a way to identify HR+/HER2- early breast cancer patients who will benefit from anthracycline therapy," said Joyce A. O’Shaughnessy, M.D., principal investigator for the FLEX Study. “I think the biologic rationale and the data underpinning the observation that High Risk 2 Luminal (by BluePrint) breast cancer patients benefit from anthracycline therapy are quite strong.” The updated NCCN Guidelines are based on a three-year analysis of outcomes
Cargill Wins 2026 BIG Innovation Award20.1.2026 13:00:00 CET | Press release
The company was honored as a Top Innovator for large-scale AI-and-data-driven innovation advancing food security, operational excellence and resilient food systems Cargill today announced it has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agriculture system. Cargill was honored in the Innovative Organizations category, alongside a cohort of 159 companies, products and leaders that are transforming industries through applied innovation and measurable real-world impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120109897/en/ Cargill has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agr
Armis Helps Italian Grocery Retailer Multicedi Strengthen Cyber Resilience20.1.2026 13:00:00 CET | Press release
Armis Centrix™ identified that 10-15% of connected assets across the organization’s network were previously unaccounted for, introducing cyber risk Armis, the cyber exposure management & security company, today announced that Multicedi, one of the leading grocery retail groups in Central and Southern Italy, is using Armis Centrix™, Armis’ Cyber Exposure Management Platform, to strengthen its cybersecurity posture. “Before introducing Armis, critical issues were addressed only when malfunctions or abnormal events had already occurred,” said Livio De Prisco, Director of Information Systems at Multicedi. “With Armis Centrix™, the approach has completely changed: rather than responding reactively, the company now has a real-time view of its entire device fleet and can manage it proactively. We can detect devices that have been added to the network, prioritize risks based on their criticality, and define action plans and budgets consistent with our operational and regulatory requirements.”
TreviPay Launches Pay by Invoice for Issuers Enabled by Visa Credentials20.1.2026 13:00:00 CET | Press release
TreviPay’s Pay by Invoice solution enables Visa issuers and their business buyers to use Visa credentials for supplier payments to unlock new B2B opportunities TreviPay announces the launch of its Pay by Invoice solution for Visa-issuing banks, enabling issuers to capture a greater share of the $58 trillion North American B2B payments market. Through this collaboration with Visa, a world leader in digital payments, TreviPay’s order-to-cash automation technology combines with Visa’s commercial payment capabilities to help issuers move fragmented B2B spend into strategic, issuer-financed, invoice-based transactions. A Murphy Research study, found 26% of corporate payments are still made with checks or rely on manual legacy ACH processes. The study also shows 78% of global B2B buyers need customization or control in their payments and invoicing workflows, with 61% preferring to pay on net terms. Pay by Invoice helps banks meet these expectations by providing suppliers with early payment (
Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI20.1.2026 11:03:00 CET | Press release
The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE: PM) today released a new white paper, “Human Cognition: The Next Frontier?”, inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the “superskill” of the future, driving progress in an era of human-machine collaboration. As AI automates routine tasks and augments knowledge work, PMI argues that nurturing and protecting cognitive capacity will be essential for organizations seeking to remain resilient and relevant. Where once technology often automated labor-intensive jobs in the quest to improve productivity, now, as intelligent systems take on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom